

In the Top 25% of 1832 Similar Sized Companies on Comparably
In the Top 40% of 932 Nearby Companies in San Francisco
3rd place versus 4 competitors rated on Comparably
Keith Grossman has over 30 years of experience in the medical device field. Grossman served most recently, and for the second time, as the President, Chief Executive Officer and director of Thoratec Corporation, leading up to its 2015 sale to St. Jude Medical. Prior to Thoratec, he served as President, Chief Executive Officer and director of Conceptus, a women’s health medical device company, leading up to its sale to Bayer Healthcare. Prior to Conceptus, Mr. Grossman served as managing director of TPG (Texas Pacific Group), a private equity firm, as a member of its healthcare investment team. Prior to TPG, Mr. Grossman served as Thoratec’s President, Chief Executive Officer and director for the first ten years of its growth as a commercial company. Mr. Grossman currently serves as Chairman of the Board of Outset Medical, Inc. (privately held), Board member of ViewRay, Inc. and previously served as a member of the Board of directors of Intuitive Surgical, Inc., Kyphon, Inc., and a number of privately held medical device companies. Mr. Grossman received a B.S. in life sciences from The Ohio State University and an M.B.A. from Pepperdine University
The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Nevro.
Based on 3 ratings, D. Keith Grossman ranks right below Boston Scientific's CEO, Michael Mahoney.
Overall, the CEO score has remained stable over the last 90 days.
Nevro ranks in the Top 25% of other companies on Comparably with 501-1,000 Employees for CEO Rating Score.
Nevro ranks in the Top 40% of other companies in San Francisco for CEO Rating Score.
